302 related articles for article (PubMed ID: 27039149)
1. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
[TBL] [Abstract][Full Text] [Related]
2. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).
Smith B; Lyakhov I; Loomis K; Needle D; Baxa U; Yavlovich A; Capala J; Blumenthal R; Puri A
J Control Release; 2011 Jul; 153(2):187-94. PubMed ID: 21501640
[TBL] [Abstract][Full Text] [Related]
4. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
5. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
Amin M; Badiee A; Jaafari MR
Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
7. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
8. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
9. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
10. Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models.
Alavizadeh SH; Akhtari J; Badiee A; Golmohammadzadeh S; Jaafari MR
Expert Opin Drug Deliv; 2016; 13(3):325-36. PubMed ID: 26578208
[TBL] [Abstract][Full Text] [Related]
11. Surrogate MRI markers for hyperthermia-induced release of doxorubicin from thermosensitive liposomes in tumors.
Peller M; Willerding L; Limmer S; Hossann M; Dietrich O; Ingrisch M; Sroka R; Lindner LH
J Control Release; 2016 Sep; 237():138-46. PubMed ID: 27364227
[TBL] [Abstract][Full Text] [Related]
12. Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models.
Jia D; Yang Y; Yuan F; Fan Q; Wang F; Huang Y; Song H; Hu P; Wang R; Li G; Liu R; Li J
Int J Pharm; 2020 Aug; 586():119541. PubMed ID: 32544521
[TBL] [Abstract][Full Text] [Related]
13. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
Cheng YA; Chen IJ; Su YC; Cheng KW; Lu YC; Lin WW; Hsieh YC; Kao CH; Chen FM; Roffler SR; Cheng TL
Biomater Sci; 2019 Aug; 7(8):3404-3417. PubMed ID: 31251311
[TBL] [Abstract][Full Text] [Related]
14. In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors.
Ding Y; Cui W; Sun D; Wang GL; Hei Y; Meng S; Chen JH; Xie Y; Wang ZQ
Drug Des Devel Ther; 2017; 11():3105-3117. PubMed ID: 29123382
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
16. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
[TBL] [Abstract][Full Text] [Related]
17. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
18. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cells.
Lee YH; Ma YT
J Nanobiotechnology; 2017 May; 15(1):41. PubMed ID: 28521752
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
